NVE Corporation (NVEC) - 10-K Summary
Business Context and Reporting Period
Company: NVE Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2009
Business Overview: NVE develops and sells spintronic devices (sensors, couplers, and MRAM technology) used to acquire, store, and transmit information. The company operates in one reportable segment, serving markets in factory automation, medical devices, and industrial control. It also engages in contract research and development, primarily with U.S. Government agencies.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 | Fiscal 2007 |
|---|---|---|---|
| Total Revenue | $23,372,269 | $20,528,812 | $16,460,830 |
| Gross Profit | $16,648,027 | $13,695,504 | $10,673,172 |
| Gross Margin | 71.2% | 66.7% | 64.8% |
| Net Income | $9,782,895 | $7,187,384 | $4,780,783 |
| Diluted EPS | $2.04 | $1.51 | $1.00 |
| Cash & Marketable Securities | $34,321,811 | $24,736,874 | $18,289,191 |
| Operating Cash Flow | $9,998,114 | $6,909,226 | $5,520,476 |
| Total Debt | $0 | $0 | $0 |
Note: The company reported no long-term debt or capital lease obligations as of March 31, 2009.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14% year-over-year to $23.4 million. This was driven by a 7% increase in product sales and an 81% surge in contract research and development (R&D) revenue.
- Profitability: Net income rose 36% to $9.8 million. Gross margin expanded to 71.2% due to manufacturing efficiencies, a favorable product mix, and higher margins on R&D contracts.
- Expense Management: R&D expenses decreased 18% due to the completion of specific projects and an increase in contract R&D obligations (which are reimbursed). SG&A expenses increased slightly (1%) primarily due to higher salaries and commissions.
- Geographic Shifts: Revenue increased 15% in the U.S. and 36% in Europe, but decreased 29% in Asia.
- Backlog: Firm contract R&D backlog increased significantly to $2.2 million from $0.9 million in the prior year, with 53% attributed to U.S. Government agencies.
Outlook, Risks, and Management Commentary
Management Commentary: Management attributes the strong fiscal 2009 performance to new R&D contracts and increased sales of medical device sensors. They note that while product sales into industrial control and factory automation decreased due to a worldwide manufacturing slowdown, medical device sales offset this decline. The company maintains a strong liquidity position with over $34 million in cash and marketable securities.
Guidance: The filing does not provide specific numerical guidance for future periods. Management states they believe working capital and cash generated from operations will be adequate through fiscal 2010.
Risks and Contingencies:
- Customer Concentration: The company relies on a few large customers (Avago, Phonak, St. Jude Medical, Starkey, and the U.S. Government). The loss of any single customer could materially impact revenue.
- Supply Chain: NVE depends on single-source suppliers for critical wafers and packaging. One key packaging vendor (CEI in Thailand) is under voluntary debt rehabilitation.
- Market Conditions: The global economic downturn has negatively impacted the semiconductor market and industrial automation sectors.
- Intellectual Property: Future revenue depends on the commercialization of MRAM by licensees and the enforcement of patent rights against competitors.
- Investment Risk: Approximately 76% of total assets are held in marketable securities, which are subject to credit and interest rate risks.
Investor Verification Checklist
- Customer Renewals: Verify the status of key supply agreements with St. Jude Medical (expires Dec 2009) and Avago Technologies (expires June 2010).
- R&D Contract Sustainability: Assess the likelihood of follow-on contracts for the 81% increase in R&D revenue, as management notes this may not be representative of future trends.
- Supply Chain Resilience: Monitor the financial stability of the packaging vendor in Thailand (CEI) and the availability of single-source wafer suppliers.
- MRAM Licensing: Track progress on MRAM licensing negotiations with Freescale/EverSpin and the commercialization efforts of existing licensees (Cypress, Honeywell).
- Investment Portfolio: Review the credit quality of the $32.4 million marketable securities portfolio, noting the unrealized losses on corporate and municipal bonds due to market conditions.